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Background: The metabolic syndrome (MetS) is associated with increased risk of cardiovascular disease. In this
study, we examine if metabolic syndrome predicts progression of atherosclerosis over 13 years.
Methods: Participants were 1442 men and 1532 women in the population-based Tromsø Study who underwent
carotid ultrasound examinations at baseline in the 4th (1994–5) and at follow-up in the 6th survey (2007–8). Of
these, 278 men and 273 women fulfilled the criteria for the MetS, defined according to a modified version of the
National Cholesterol Education Program Adult Treatment Panel III (NCEP, ATPIII). Carotid atherosclerosis was
assessed as total plaque area (TPA) and mean intima-media thickness (IMT) at follow-up and as change in IMT and
TPA from baseline to follow-up. Associations between MetS and its components and carotid atherosclerosis were
assessed in linear regression models adjusted for age, total cholesterol and daily smoking, stratified by sex.
Results: IMT and TPA levels at follow-up (p < 0.0001) and progression of TPA (p = 0.02) were higher in the MetS
group compared to the non-MetS group. In stepwise multivariable models, MetS was associated with TPA
(β= 0.372 mm2, p = 0.009) and IMT (β= 0.051 mm, p < 0.0001) in men, and with IMT (β= 0.045 mm, p = 0.001) in
women after 13 years of follow-up, but not with progression of IMT or TPA. In analyses stratified by age, MetS
predicted progression of IMT (β= 0.043 mm, p = 0.046) and TPA (β= 1.02 mm2, p = 0.002) in men below 50 years of
age. Hypertension was predictive of follow-up TPA and IMT in both genders and of progression of TPA in women.
Impaired glucose tolerance was associated with follow up levels of IMT and TPA as well as progression in IMT in
men. None of the other components of MetS were associated with progression of atherosclerosis.
Conclusions: Subjects with MetS had higher levels of IMT and TPA at follow up than those without MetS. Mets
predicted progression of IMT and TPA in those below 50 years of age, but not in other age groups, indicating that
MetS may be involved in the initiation of the atherosclerotic process.
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http://www.cardiab.com/content/11/1/77Metabolic syndrome (MetS) is a cluster of metabolic and
non-metabolic cardiovascular risk factors, including in-
sulin resistance, dyslipidaemia, visceral adiposity and
hypertension. However, the pathophysiological basis and
utility of MetS are debated, although several studies have
shown associations between MetS and increased risk of
cardiovascular disease (CVD) [1-7].
Atherosclerosis is the underlying process of a majority
of cardiovascular disease and mortality. While the clin-
ical manifestations of atherosclerosis usually do not
occur until middle age, atherosclerosis develops early in
life. Noninvasive ultrasonographic assessment of carotid
intima-media thickness (IMT) and total plaque area
(TPA) is suitable for evaluation of the burden of athero-
sclerosis, and are predictive of future risk of CVD. Al-
though inter-correlated, measurements of IMT and TPA
are thought to reflect different biological aspects of and
stages in the development of atherosclerosis. Whereas
TPA measures formed plaques, IMT can be measured
where no focal disease is present. Both cross-sectional
and prospective studies have shown association between
MetS and IMT [1,3,8-10]. Data on associations between
plaque measurements and MetS are scarce [6,9,11]. In a
study on 166 members of the Canadian Oji-Cree com-
munity, a population with one of the world`s highest
prevalence rates of the MetS, MetS was associated with
IMT and total plaque volume after 7 years of follow-up
[9]. In the prospective Bruneck study, subjects with
MetS had higher progression of atherosclerosis as
assessed by formation of new plaques and carotid sten-
osis [11]. In a cross-sectional study, plaque presence was
associated with metS in women only [6].
In the prospective population-based Tromsø Study, we
explored the relationship between MetS and progression
of atherosclerosis in 2795 persons after 13 years. Infor-
mation on MetS and cardiovascular risk factors were
obtained at baseline. Carotid atherosclerosis, assessed as




The Tromsø Study is a longitudinal population-based
health study with repeated surveys of the adult popula-
tion in the municipality of Tromsø, Norway [12]. The
study has been approved by the Regional Committee for
Medical and Health Research Ethics, the Norwegian Dir-
ectorate of Health and the Data Inspectorate.
Subjects eligible for the present study were those who
participated in ultrasound examination in the 4th (1994–
1995) and 6th survey (2007–2008) of the Tromsø Study.
The 4th survey consisted of two screening visits, and
ultrasound examination of the carotid arteries was done
at the 2nd visit. All inhabitants of Tromsø aged 55–74 years and random 5-10% samples of subjects in the
age groups 20–54 years and 75–84 years were invited to
the 2nd visit, and 6885 subjects attended (79% of the eli-
gible population). Carotid ultrasound examination was
performed in 6727 subjects. During follow-up, 1451 per-
sons died and 486 moved from Tromsø. Forty-one sub-
jects were excluded because they had withdrawn their
written consent to further research. Of the remaining
4750 subjects who were still alive and living in Tromsø,
2974 subjects (62.6%) attended the carotid ultrasound
examination in the 6th survey in 2007–2008, and were
included in the present study. All included participants
gave informed, written consent.
Baseline risk factors
At baseline, information on diabetes mellitus, use of in-
sulin and/or anti diabetic drugs, smoking habits, history
of cardiovascular diseases and treated hypertension (never/
previous/current) were obtained from self-administered
questionnaires. Height and weight were measured with
subjects wearing light clothing and without shoes. BMI
was calculated as weight in kilograms divided by squared
height in meters (kg/m2). Waist circumference was mea-
sured at the umbilical line. Blood pressure was recorded
three times at one-minute intervals after two minutes of
seated resting with the use of an automatic device (Dina-
map Vital Signs Monitor 1846, Criticon) and by specially
trained technicians. The mean of the last two recordings
was used in the report. Analyses of non-fasting serum
total cholesterol and triglycerides were done using com-
mercial kits. Serum high density lipoprotein (HDL) choles-
terol was measured after the precipitation of lower-density
lipoprotein with heparin and manganese chloride. The low
density lipoprotein (LDL) concentration was calculated
according to Friedewald’s formula: LDL-cholesterol =Total
cholesterol – HDL-cholesterol – (0.45 x triglycerides) in
2961 subjects with triglyceride levels below 4.52 mmol/L.
Lipid levels were measured twice with an interval of
4–12 weeks and the averages of these values were used in
the analyses. Serum uric acid was measured by photometry
with COBASW instruments (Roche diagnostics, Switzer-
land) using an enzymatic colorimetric test, the uricase/PAP
method. Glycosylated haemoglobin (HbA1C) levels were
measured with a liquid chromatographic procedure. All
analyses were performed at the Department of Clinical
Chemistry, University Hospital of Northern Norway.
Definition of metabolic syndrome
MetS was defined according to the National Cholesterol
Education Program Adult Treatment Panel III (NCEP,
ATPIII) [13]. According to this definition, the MetS is
present when three or more of the following five criteria
are fulfilled; abdominal obesity, hypertriglyceridemia, low
HDL-cholesterol, hypertension, or elevated fasting glucose.
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http://www.cardiab.com/content/11/1/77Abdominalobesityisdefinedaswaistcircumference≥102cm
in men and≥ 88 cm in women. Hypertriglyceridemia is
definedaselevated triglycerides≥ 150mg/dL(1.7mmol/L)or
self-reported lipid lowering drug treatment. Low HDL
cholesterol is defined as < 40 mg/dL (1.0 mmol/L) for men
and<50 mg/dL (1.30 mmol/L) for women or self-reported
lipid lowering drug treatment. As fasting glucose was not
measured in the Tromsø Study, HbA1c ≥6.1% and/or
non-fasting plasma glucose >11.1 mmol/L and/or self-
reported diabetes and/or use of anti-diabetic medication
was defined as impaired glucose tolerance. Hypertension
was defined as elevated systolic blood pressure≥ 130mmHg,
or diastolic blood pressure≥ 85 mmHg, or self-reported
current antihypertensive drug treatment [14].
Carotid ultrasound measurements
High-resolution B-mode ultrasonography at baseline was
performed with Acuson Xp10 128, ART-upgraded du-
plex scanners equipped with 7.5 MHz linear array trans-




Age 60.4 (7.3) 56.0 (10.4)
Systolic blood pressure (mmHg) 153.1 (20.9) 135.6 (20.7)
Diastolic blood pressure (mmHg) 86.3 (12.9) 77.9 (11.6)
Hypertension treatment (%) 59 (21.6) 80 (6.5)
Components of metabolic syndrome
Waist circumference (cm) 93.8 (9.1) 81.35 (8.4)
Triglycerides (mmol/L)† 2.29 (0.87) 1.18 (0.54)
HDL (mmol/L) 1.37 (0.32) 1.75 (0.38)
Diabetes (%) 18 (6.6) 8 (0.7)
HbA1c % 5.68 (0.64) 5.35 (0.34)
Impaired glucose tolerance (yes/no) 53 (20.0) 22 (1.8)
Uric acid (μmol/L)† 308.75 (87) 255 (73.5)
Total cholesterol (mmol/L) 7.22 (1.19) 6.57 (1.3)
LDL-cholesterol (mmol/L) 4.84 (1.09) 4.29 (1.18)
Daily smoking (yes/no) 59 (21.6) 364 (28.6)
Measurements of atherosclerosis
Baseline mean IMT(mm) 0.85 (0.16) 0.77 (0.15)
Plaque presence (%) 132 (48.4) 383 (31.0)
Baseline TPA (mm2)† 7.84 (13.75) 4.55 (9.66)
Use of medication
Antihypertensive (yes/no) 59 (21.6) 80 (6.5)
Lipid-lowering (yes/no) 20 (7.3) 3 (0.2)
Antidiabetic (yes/no) 10 (3.7) 4 (0.39)
* Numbers are means (SD) or numbers (%), † median (interquartile range).
HDL; high-density lipoprotein cholesterol, LDL; low-density lipoprotein cholesterol. H
plaque area.
The Tromsø Study.12 MHz transducers were used at follow-up [15]. Sub-
jects were examined in the supine position with the head
slightly tilted to the opposite side. No fixed angle of
insonation was used; the sonographers were instructed
to view the arteries from all possible angles, in order to
find the optimal view for visualization of plaque and
IMT in each subject. The far- and near walls of the right
common carotid artery (CCA), bifurcation (bulb) and in-
ternal carotid artery (ICA) (six locations) were scanned
for the presence of plaques. A plaque was defined as a
localized protrusion into the vessel lumen with thicken-
ing of the vessel wall of more than 50% compared to the
adjacent IMT. The outline of each plaque was marked
manually on still images, with calculation of plaque area.
In subjects with more than one plaque, TPA was calcu-
lated as the sum of all plaque areas. Semi-automated
ECG-triggered measurement of IMT was performed in
10 mm segments of the far (CCA-FW-IMT) and near
wall (CCA-NW-IMT) of the CCA and in the most prox-
imal 10 mm far wall segment of the bulb (BULB-FW-metabolic syndrome, by sex
Men
Metabolic syndrome
p Yes No p
<0.0001 55.5 (8.3) 56.2 (9.2) 0.3
<0.0001 146.0 (16.2) 139.0 (18.1) <0.0001
<0.0001 87.3 (10.6) 82.6 (11.4) <0.0001
<0.0001 44 (15.9) 73 (6.4) <0.0001
<0.0001 102.5 (8.4) 92.7 (7.1) <0.0001
<0.0001 2.63 (1.04) 1.50 (0.74) <0.0001
<0.0001 1.10 (0.26) 1.43 (0.34) <0.0001
<0.0001 11 (4.0) 6 (0.5) <0.0001
<0.0001 5.47 (0.62) 5.32 (0.39) <0.0001
<0.0001 34 (12.45) 14 (1.22) <0.0001
<0.0001 400.5 (106) 339 (87.5) <0.0001
<0.0001 6.75 (1.17) 6.46 (1.1) 0.0003
<0.0001 4.50 (1.05) 4.36 (0.99) 0.04
0.03 73 (26.3) 333 (29.0) 0.4
<0.0001 0.87 (0.17) 0.83 (0.17) 0.0008
<0.0001 137 (49.3) 484 (421) 0.03
<0.0001 9.48 (13.55) 7.75 (13.58) 0.05
<0.0001 44 (15.9) 73 (6.4) <0.0001
<0.0001 28 (10.7) 6 (0.59) <0.0001
<0.0001 6 (2.2) 4 (0.4) 0.001
bA1c; glycosylated hemoglobin, IMT; intima-media thickness, TPA; total
Herder et al. Cardiovascular Diabetology 2012, 11:77 Page 4 of 9
http://www.cardiab.com/content/11/1/77IMT). Mean IMT from the 3 pre-selected images was
calculated for each location. If present in the predefined
location of interest, plaques were included in the IMT
measurements. The average of mean IMT from the three
locations was used in the analyses (hereafter referred to
as IMT). Final reading of IMT and plaque area was done
off line using the automated Artery Measurement Sys-
tem II [16]. The inter- and intra-observer and inter-
equipment reproducibility of IMT and plaque measure-
ments was acceptable [15,17-19].Statistical analysis
Stata SE 11 (StataCorp LP, College Station, TX, USA)
and the SAS software, version 9, were used for all ana-
lyses. Differences between subjects with and without
MetS were analyzed using t-test (continuous variables)
Wilcoxon rank-sum test and χ ² (dichotomous variables).
Values are presented as means (SD) or numbers (%).
TPA was square-root-transformed to approximate nor-
mal distribution. Changes in IMT and square-root-
transformed TPA were calculated by subtracting the
value at baseline from the follow-up value (ΔIMT and
ΔTPA). Linear regression models were fitted with IMT
and TPA as dependent variables and MetS, age, total
cholesterol and smoking as independent variables. Simi-
larly, stepwise linear multivariable models with forward
selection and significance level 0.05 for entry into the
model were fitted with each component of the metabolic
syndrome entered as separate independent variables, to-
gether with age, total cholesterol and smoking. Inter-
action with sex was examined with IMT and TPA as the
dependent variable and sex, risk factor, and sex*riskTable 2 Carotid atherosclerosis after 13-years in subjects with
Metabolic syndrome
Yes No
Age, years N IMT, mm N IMT, mm P*
0-49 81 0.940 483 0.818 <0.00
50-59 224 1.014 965 0.964 <0.00
60-69 213 1.088 835 1.041 0.008
≥70 32 1.135 101 1.059 0.09
Total 550 1.039 2384 0.966 <0.00
Age, years N ΔIMT, mm N ΔIMT, mm P*
0-49 81 0.185 483 0.143 0.009
50-59 222 0.169 965 0.160 0.5
60-69 208 0.195 832 0.176 0.2
≥70 32 0.157 101 0.126 0.5
Total 543 0.178 2381 0.165 0.13
* p for differences between subjects with and without metabolic syndrome.
IMT; intima-media thickness at follow-up, TPA; total plaque area at follow-up, ΔIMT;
total plaque area from baseline to follow-up.
The Tromsø Study.factor as independent variables. There was significant
interaction between sex and MetS in the IMT models,
all analyses were therefore stratified by sex. Further
adjustments were made for uric acid and use of lipid-
lowering, anti-platelet and antihypertensive drugs at
baseline and follow-up. Two-sided p-values < 0.05 were
considered statistically significant.Results
Baseline characteristics of the 273 women and 278 men
who met the criteria for MetS are shown in Table 1.
Women with MetS were older and fewer smokers than
women without MetS. Subjects with MetS had increased
IMT, more plaques and larger TPA at baseline (Table 1).
Mean observation time was 13.2 years. Follow-up
levels of IMT and TPA were higher in subjects with
MetS than in controls, most pronounced in those below
70 years of age. Change in IMT and TPA was associated
with Mets only in those younger than 50 years (Table 2,
Figures 1 and 2).
In stepwise multiple regression analysis, MetS was inde-
pendently associated with follow-up IMT (β=0.051 mm,
p<0.0001) and TPA (β=0.372 mm2, p=0.009) in men.
MetS predicted follow-up IMT (β=0.045 mm, p=0.001) in
women only (Table 3). In analyses stratified by age, MetS
predicted progression of IMT (β=0.043 mm, p=0.046)
and TPA (β=1.02 mm2, p=0.002) in men below 50 years
of age, but not in the total population.
Uric acid level (log-transformed) was not independently
associated with IMT or TPA in multivariable analyses, and
further adjustment for uric acid did not change did not
change the estimates. Adjustment for lipid-lowering,and without metabolic syndrome, by age
Metabolic syndrome
Yes No
N TPA, mm2 N TPA, mm2 P*
01 79 10.748 479 5.737 0.0001
01 218 18.146 956 14.569 0.02
209 25.494 830 21.814 0.06
31 28.647 99 24.543 0.46
01 537 20.524 2364 15.740 <0.0001
N ΔTPA, mm2 N ΔTPA, mm2 P*
79 7.858 477 4.031 0.0006
218 9.857 953 9.203 0.6
208 15.363 826 13.116 0.4
31 10.951 99 11.227 0.9
536 11.763 2355 9.613 0.02
change in intima-media thickness from baseline to follow-up, ΔTPA; change in
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Figure 1 a: Mean IMT (mm) at follow up in subjects with and without metabolic syndrome (MetS), by age group. Error bars represent
95% confidence intervals. b: Mean TPA (mm²) at follow up in subjects with and without metabolic syndrome (MetS), by age group. Error bars
represent 95% confidence intervals.
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weakened the relationship between MetS and follow-up
levels of IMT and TPA, but not substantially.
In stepwise multivariable analyses with each compo-
nent of the MetS entered separately and adjusted for
age, LDL-cholesterol and smoking, hypertension was
consistently associated with follow-up levels of TPA and
IMT in both sexes and with progression of TPA in
women (Table 4). Low HDL-cholesterol levels were asso-
ciated with follow-up levels of IMT women. Impaired
glucose tolerance was associated with follow-up levels of
IMT and TPA and with progression of IMT in men.Hypertriglyceridemia was associated with follow up
levels of IMT in both men and women, but not with
progression. We found no association between abdom-
inal obesity and IMT or TPA.Discussion
The main finding of our study was that MetS was an in-
dependent predictor of follow-up IMT and TPA in men
and women. MetS was an independent predictor of pro-
gression of IMT and TPA in subjects below 50 years of
age, but not in other age groups.
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Figure 2 a: Change in IMT in subjects with and without metabolic syndrome (MetS), by age group. Error bars represent 95% confidence
intervals. b: Change in TPA in subjects with and without metabolic syndrome (MetS), by age group. Error bars represent 95% confidence intervals.
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http://www.cardiab.com/content/11/1/77Our finding of increased IMT in subjects with MetS
after 13 years of follow-up is in line with results from
previous cross-sectional studies [1,3,8,9]. Longitudinal
data are scarce. In a posthoc analysis on 2334 hyperten-
sive patients in the European Lacidipine Study on Ath-
erosclerosis (ELSA), progression of IMT was slightly
greater in patients with MetS, but this was not signifi-
cant after adjustment for other cardiovascular risk fac-
tors [20]. In our study, change in IMT and TPA was
most pronounced in younger age groups. This is in line
with the results from a population-based study of 1809
young Finns aged 32 ± 5 years, where MetS was asso-
ciated with progression of IMT in subjects aged 24–39 years[10]. We found no association in the older age
groups. This may indicate that MetS is more important
for the early stages of the atherosclerotic process, a
process which accelerates in the 4th to 5th decade. How-
ever, in a study on 102 elderly women, incident MetS
predicted progression of IMT after 12-years follow-up
[21].
Few studies have assessed the relationship between
MetS and plaque measurements [6,9,11,22]. In a multi-
ethnic cross-sectional study, MetS and the number of
MetS components was independently associated with
plaque presence [22]. A prospective study on 166 Cree-
Indians showed that MetS at baseline predicted follow-
Table 3 Associations* between metabolic syndrome and carotid atherosclerosis after 13 years
Follow-up levels Change from baseline to follow-up
IMT (mm) TPA† (mm²) ΔIMT (mm) ΔTPA† (mm²)
β p{ β p{ β p{ β p{
Men
Metabolic syndrome 0.051 0.0003 0.372 0.009 - - - -
Age 0.008 <0.0001 0.074 <0.001 - - 0.031 <0.0001
LDL cholesterol 0.016 0.004 0.232 <0.001 - - - -
Daily smoking 0.038 0.002 0.564 <0.001 - - 0.514 0.001
Women
Metabolic syndrome 0.045 0.0004 - - - - - -
Age 0.008 <0.0001 0.049 <0.0001 0.002 <0.0001 0.031 <0.0001
LDL cholesterol 0.022 <0.0001 0.227 <0.0001 - - 0.204 0.0002
Daily smoking - - 0.503 <0.0001 0.033 0.001 0.498 0.0002
*Stepwise multivariable linear regression analysis with forward selection and significance level 0.05 for entry into the model.
†square-root-transformed values were used in the analyses.
{p values for β-coefficients.
IMT; intima-media thickness, TPA; total plaque area, LDL; low-density lipoprotein cholesterol.
The Tromsø Study.
Table 4 Associations* between components of metabolic syndrome and carotid atherosclerosis after 13 years
Follow-up levels Change from baseline to follow-up
IMT (mm) TPA† (mm²) ΔIMT (mm) ΔTPA† (mm²)
β p{ β p{ β p{ β p{
Men
Age 0.008 <0.0001 0.102 <0.0001 - - 0.031 <0.0001
Components of MetS
Hypertension 0.045 0.0004 0.642 0.0003 - - - -
Abdominal obesity - - - - - - - -
Hypertriglyceridemia 0.029 0.01 - - - - - -
Low HDL-level - - - - - - - -
Impaired glucose tolerance 0.102 0.001 1.129 0.01 0.075 0.006 - -
LDL cholesterol 0.013 0.02 0.263 0.0006 - - - -
Daily smoking 0.04 0.0001 1.134 <0.0001 0.021 0.006 0.516 0.001
Women
Age 0.008 <0.0001 0.073 <0.0001 0.002 <0.0001 0.027 <0.0001
Components of MetS
Hypertension 0.041 <0.0001 0.643 <0.0001 - - 0.308 0.02
Abdominal obesity - - - - - - - -
Hypertriglyceridemia 0.026 0.014 - - - - - -
Low HDL-level 0.031 0.012 - - - - - -
Impaired glucose tolerance - - - - - - - -
LDL cholesterol 0.021 <0.0001 0.425 <0.0001 - - 0.195 0.0004
Daily smoking 0.025 0.025 0.956 <0.0001 0.034 0.0008 0.537 <0.0001
* Stepwise multivariable linear regression analysis with forward selection and significance level 0.05 for entry into the model.
†square-root-transformed values were used in the analyses.
{p values for β-coefficient.
MetS; metabolic syndrome, HDL; high-density lipoprotein cholesterol, LDL; low-density lipoprotein cholesterol.
The Tromsø Study.
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http://www.cardiab.com/content/11/1/77up levels of IMT, but not total plaque volume, a measure
which is strongly correlated with TPA. However, change
in IMT and total plaque volume was not assessed. In the
Bruneck study, MetS was associated with 5-year change
in atherosclerosis as assessed by novel plaque and sten-
osis formation [11].
Previous studies found no clear evidence that MetS
predicted IMT progression better than expected from
the sum of the individual components [10]. In our study,
hypertension was the one component most consistently
associated with follow-up levels of carotid atheroscler-
osis among men and women. Hypertension was also in-
dependently associated with progression of TPA in
women. Impaired glucose tolerance was associated
with follow up IMT and progression of IMT in men. In
a systematic review, three of nine of cross-sectional
studies found significantly larger IMT in subjects with
impaired glucose tolerance [23]. Both low HDL-levels
and hypertriglyceridemia were associated with follow-up
levels of IMT and TPA, but not with progression
of atherosclerosis.
Increased use of medication that may influence the
atherosclerotic process during follow-up could have con-
founded our results. Use of lipid-lowering, antiplatelet
and antihypertensive drugs increased during follow-up,
most pronounced for use of lipid-lowering drugs (from
1.9% to 26.9%). The association between MetS and IMT
and TPA was somewhat weakened with adjustment for
use of medication at follow-up, but not substantially,
and this could not explain the lack of association be-
tween MetS and progression of atherosclerosis.
In a previous study, serum uric acid level was associated
with MetS and carotid atherosclerosis in patients diag-
nosed with diabetes mellitus type 2 [24]. We found no in-
dependent association between serum uric acid and
carotid atherosclerosis in our population-based study. Pos-
sible links between metabolic dysfunction and atheroscler-
osis may be secretion of adipokines by adipose tissue.
Several adipokines have been reported to promote arterial
stiffness, inflammation and atherosclerosis in subjects with
diabetes and coronary heart disease [25-27]. Adipokines
were not measured in the Tromsø Study.
In general, it is more difficult to detect associations be-
tween risk factors and change in atherosclerosis as opposed
to single measurements [15,28]. Measurements of progres-
sion of atherosclerosis are more prone to errors than single
measurements because random measurement errors at
baseline and follow-up are accumulated. This can attenuate
the differences aimed to be detected, and may preclude the
detection of a positive relationships between MetS and
change in atherosclerosis as opposed to single measure-
ment of atherosclerosis at follow-up.
Our study has some important limitations. As observed
in many other large population-based epidemiologicalstudies, the overall attendance rates of the Tromsø Study
fell from 77% in 1994–1995 to 64% in 2007–8 [12]. The at-
tendance at follow-up was lower in those with MetS at
baseline. During follow-up, the proportion that moved
from Tromsø was lower in the MetS group compared to
the non-MetS group (5.9% vs. 7.9%, p =000.4), but this
was by far outweighed by selection bias due to higher
mortality in those with than without MetS (28.8% vs
19.6%, p <0.0001). Further selection bias may have oc-
curred due to higher morbidity in the MetS group [12].
Furthermore, the attendance rates at follow-up were low
in subjects ≥70 years, which calls for caution in making
inferences about this group.
Conclusion
In conclusion, we found that MetS was associated with
IMT and TPA levels at follow up. In analyses of the dif-
ferent components of MetS, hypertension showed the
most consistent positive association with carotid athero-
sclerosis. MetS was associated with progression of IMT
and TPA only in those below 50 years of age. The results
may indicate that MetS may be involved in the initiation
of the atherosclerotic process.
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